Bioactive half-sandwich Ru( ii ) arene imidazolyl–benzylidene phenolate complexes: synthesis, in silico studies and cytotoxicity against HeLa and MCF-7 cells
Year: 2026
Type: article
Abstract: for BSA). The molecular docking studies supported the experimental results by elucidating favourable binding modes with both target biomolecules. Furthermore, TD-DFT calculations were carried out to analyze the electronic transitions and molecular properties of the complexes. The antiproliferative activity of these complexes was tested on different human cell lines, including human breast (MCF-7), cervical (HeLa), and non-cancerous human embryonic kidney (HEK-293) cells. Among these, RuL1 = 28.74 ± 0.43 µM and RuL2 = 21.88 ± 1.21 µM showed the highest cytotoxicity with the highest efficacy towards MCF-7 cells over the HeLa cells. Furthermore, RuL1 and RuL2 displayed a very low toxicity on HEK-293 cells, signalling their selectivity. Mechanistic studies revealed that these lead complexes stimulated the generation of intracellular reactive oxygen species (ROS), as confirmed by DCFH-DA staining, and induced apoptosis, as evidenced by acridine orange/ethidium bromide staining. The experimental and theoretical findings show that the half-sandwich Ru(ii) arene imidazolyl-benzylidene phenolate complexes can be utilized to create selective anticancer drugs based on ruthenium.
Source: RSC Advances
DOI: 10.1039/d6ra07948b
Authors: Shivabasayya V. Salimath(Data curation, Investigation, Methodology, Writing – original draft), Arunkumar V. S(Data curation, Investigation), Srushti S. Gundakanal(Data curation, Investigation), Arjita Ghosh(Methodology, Validation), Anbalagan Moorthy, Madhvesh Pathak(Resources, Supervision, Writing – review & editing), Siddappa A. Patil(Conceptualization, Resources, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,042
Awards: G9001340708, G9001361443
OpenAlex ID: W7225635479
